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The 5*-noncoding region (5*-NCR) of the hepatitis C
virus (HCV) RNA genome serves as an internal ribosome
entry site (IRES) and mediates translation initiation in a
cap-independent manner. Previously, we reported the
interaction between La antigen and the HCV IRES,
which appeared to occur in the context of initiator AUG.
It was further shown that HCV IRES-mediated transla-
tion was stimulated in the presence of human La anti-
gen. In this study, we have defined the cis- and trans-
acting elements responsible for La-5*-NCR interactions
and established the dependence of the HCV IRES effi-
ciency on cellular La antigen. During the La-IRES inter-
action, initiator AUG but not the neighboring codons
was found to be the direct target of La binding. The C
terminus effector domain-dependent modulation of La
binding to the HCV IRES is demonstrated by deletion
and substitution mutagenesis of the protein. An RNA
systematic evolution of ligands by exponential enrich-
ment (SELEX), generated against La protein that selec-
tively binds La in HeLa lysates and competes for the
protein binding to the 5*-NCR, was used to demonstrate
the requirement of La for the HCV IRES function in the
context of mono- and dicistronic mRNAs. Sequestration
of La antigen by the RNA SELEX in HeLa translation
lysates blocked the HCV and poliovirus IRES-mediated
translation in vitro. The functional requirement of La
protein for the HCV IRES activity was further estab-
lished in a liver-derived cell line and in an add-back
experiment in which the inhibited IRES was rescued by
recombinant human La. These results strongly argue for
the novel role of La protein during selection of the ini-
tiator AUG and its participation during internal initia-
tion of translation of the HCV RNA genome.
The eukaryotic mRNAs contain short, unstructured 59-non-
coding region (59-NCR)1 and are usually translated by cap-de-
pendent mechanism (see Refs. 1–3 for review). In this scheme,
the translation is initiated through binding of initiation fac-
tor-4F (eIF-4F) to the cap structure via its eIF-4E subunit. This
event is followed by joining of 43 S ribosomal complex that
consists of 40 S subunit, eIF-3, Met-tRNAi and GTP-bound
eIF-2. In contrast, a few cellular and viral mRNAs are trans-
lated by a distinct mechanism (4–7) because of their highly
structured and relatively longer 59-NCR. These structural cis-
elements constitute internal ribosome entry site (IRES) that
promote assembly of initiation complex independent of the 59
end and thus, mediate internal initiation in a cap-independent
manner. A clinically important positive strand RNA virus, hep-
atitis C virus (HCV), which causes a variety of liver diseases in
humans including hepatocellular carcinoma (8–10), has also
been shown to translate by cap-independent mechanism
through its unique IRES structure (11–17). Almost the entire
59-NCR (341 nt) of the HCV RNA except 40 nt at the extreme 59
end has been shown to function as an IRES element (14, 16).
The HCV IRES also extends to a short stretch (nt 12–30)
downstream of the initiator AUG codon (18, 19). A pseudoknot
structure (Fig. 1) preceding the translation start-site is another
unique feature of the HCV IRES that is highly conserved
among HCV genotypes and pestiviruses (17, 20). The HCV
IRES, like other viral and cellular IRES elements, serves as a
substrate for binding of multiple cellular factors. Among cellu-
lar proteins that participate during cap-independent transla-
tion initiation, two non-canonical translation initiation factors,
polypyrimidine tract-binding protein (PTB) and La antigen
(p52 or SS-B) are recognized for their ability to bind several
viral 59-NCRs (see Refs. 2 and 6 for reviews). The functional
importance of both the proteins during internal initiation of
translation has been reviewed in detail (21).
La antigen is a multifunctional phosphoprotein that was
originally identified as an autoantigen in patients with auto-
immune disorders (see Ref. 22 for review). Several studies have
provided evidence for helicase activity of La antigen (23–25).
The human La antigen contains three putative RNA recogni-
tion motifs (RRM) and a basic region followed by a stretch of
acidic region at the C terminus (26). The C terminus also
contains a homodimerization domain that is required for the
function of La in enhancing translation of poliovirus RNA (27).
Although a fraction of La antigen is found in the cytoplasm,
majority of the protein is localized in the nucleus. However,
cellular stress such as that resulting from a viral infection
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causes redistribution of the nuclear La to the cytoplasm (28). In
the nucleus, La antigen transiently associates with the 39 oli-
go(U) terminus of the RNA polymerase III transcripts and
facilitates transcription termination and recycling of transcrip-
tion complexes for reinitiation process (29). Phosphorylation of
Ser-366 residue of La antigen by casein kinase II modulates its
role in transcription but does not affect its RNA binding ability
(30). In the cytoplasm, La antigen is associated with a subset of
small ribosomal subunit, possibly by direct association with 18
S rRNA (31). La protein has been shown to interact with the
59-NCR or 59 stem-loop structures of poliovirus (28), rubella
virus (32), influenza virus (33), sindbis virus (34), the human
immunodeficiency virus TAR element (35), vesicular stomatitis
virus (36) and rabies virus (37). For the most part, these La
interactions with viral RNA elements do not appear to be
mediated by the 39 terminal oligouridylate sequences that are
characteristics of La protein’s prototypical interactions with
pre-processed polIII transcripts. RNA selection experiments
with La protein have revealed a novel CACAA motif that may
account for some non-protypical RNA interactions (38).2 One
RNA species, pre-tRNAMet elongator (termed C5 RNA by
Harada et al. (Ref. 39)) was found to have a unique relationship
to La protein, as determined by its ability to bind deletion
mutant La 22–408 that was unable to bind any polIII tran-
scripts in HeLa cells extracts (38). The C5 RNA contains both
39 oligouridylates as well as the CACAA motif. The presence of
a double binding motif likely accounts for the increased affinity
of C5 RNA relative to other polIII transcripts. Many of the viral
RNAs that interact with La protein also contain close or exact
matches to the CACAA motif within their 59-NCR sequences,
suggesting that this element may play a role in translational
regulation by La protein.
The aberrant translation initiation of poliovirus IRES-medi-
ated RNA is corrected in the presence of La antigen that is also
accompanied by a modest stimulation of translation (28, 40). La
binding to the human immunodeficiency virus TAR structure
alleviates the translational repression exerted by TAR on the
downstream reporter gene (41). We have recently shown that
La antigen interacts with the HCV IRES, which leads to sig-
nificant level of stimulation of the HCV IRES-dependent trans-
lation (42). One of the interesting and novel aspects of this
interaction is that it occurred in the context of the initiator
AUG.
Here, we have further characterized cis- and trans-elements
involved in the La-59-NCR interactions. The functional impor-
tance of these interactions during trans-activation of the HCV
IRES is investigated using mutants derived from the HCV
59-NCR as well as those in the La protein. An RNA systematic
evolution of ligands by exponential enrichment (SELEX) ligand
that specifically interacts with La protein inhibited the HCV
IRES-mediated translation in a liver derived cell line and HeLa
lysates supporting the in vivo functional relevance of that
interaction. The data presented here further reinforces our
previous observations that initiator AUG codon of the HCV
RNA is an essential recognition motif of La binding. This in-
teraction appears to be responsible for the La-dependent trans-
lation initiation of the HCV RNA.
MATERIALS AND METHODS
Construction of Plasmid DNA—The construction of recombinant
plasmids were carried out by standard protocols. The plasmid pNCR-
C(AUG) contains full-length HCV 59-NCR (HCV-1) followed by 15 nt of
the core region (42). The plasmid NCR-C(DAUG) is similar to the
NCR-C(AUG), except that it lacks initiator AUG at nt 342. The AUG
deletion in this plasmid was carried out by QuickChange site-directed
mutagenesis method (Stratagene). Using similar strategy, the plasmids
pNCR-C(DACC), pNCR-C(DC2), pNCR-C(DC3), and pNCR-C(DC4) were
constructed, which contain deletions of ACC (nt 339–341) and codons 2,
3, and 4 of the core, respectively. pNCR-C(D1–83) was derived from the
wild type plasmid pNCR-C(AUG) in which nt 1–83 at the extreme 59
end of the HCV 59-NCR was enzymatically deleted using SalI and NcoI.
Polymerase chain reaction-based strategy was employed to construct
plasmids pNCR-C(D1–120) and NCR-C(D1–135). Both the plasmids
represent HCV 59-NCR sequence of NCR-C(AUG), except that they lack
120 and 135 nt from the 59 end of the NCR, respectively. The plasmid
NCR-C(AUG) was mutated at nt positions 126–129 (CUCC to AGAA)
and 327–329 (CGU to GCA) of the HCV 59-NCR to construct pNCR-C(SI
Mut) and pNCR-C(SII Mut), respectively. The plasmid NCR-C(Py-III
Mut) was constructed by substitution of UUUCU to AAAGA at nt
194–198 in the pNCR-C(AUG). The nt sequence in these plasmids were
confirmed by dideoxyribonucleotide sequencing method. The construc-
tion of His-tagged La encoding cDNA is described in detail by Goodier
et al. (26). Selection of high affinity C5 RNA ligand against La antigen
by SELEX method and construction of plasmid pC5-SP64 that ex-
presses C5 RNA is described previously (38).
In Vitro Transcription—RNA transcripts were synthesized in vitro
from linearized plasmid DNA that was purified by elution of the desired
fragments from the agarose gels after digestion with an appropriate
restriction endonuclease. The pNCR-C(AUG) and all its derivatives
were linearized with EcoRI and transcribed with T7 RNA polymerase
using standard protocols. The plasmids pT7C1–341 (16) and pPB305
were linearized by HpaI and transcribed by T7 RNA polymerase to
produce HCV and Thieler’s murine encephalitis virus (TMEV) 59-NCR
containing monocistronic luciferase RNA, respectively. The plasmid
T7P5NCLuc was linearized with NheI and transcribed with T7 RNA
polymerase to generate monocistronic RNA containing poliovirus 59-
NCR followed by luciferase sequence. These monocistronic RNAs will
thus contain respective IRES elements fused with the luciferase open
reading frame followed by poly(A) tail. Plasmid pC5-SP64 and pGEM-4
were linearized with DraI and EcoRI, respectively, for the transcription
with T7 RNA polymerase. For the preparation of a mutant C5 SELEX,
pC5-SP64 was digested with Bsp1286I and transcribed similarly. The
capped RNAs were synthesized in the presence of m7G(59)ppp(59)G cap
analogue using Ampliscribe T7 transcription kit (Epicenter Technolo-
gies). The plasmid pRL-HCV1b, which encodes upstream Renilla lucif-
erase followed by the HCV IRES (nt 1–357 of the HCV genotype 1b)
linked to the second reporter firefly luciferase gene (56), was linearized2 D. J. Kenan and J. D. Keene, manuscript in preparation.
FIG. 1. Schematic representation of computer-generated RNA
folding model of the HCV 5*-NCR as proposed by Honda et al.
(53) and Wang et al. (20, 54). The conserved AUGs, three putative
polypyrimidine-tracts (Py), as well as stem I (SI) and stem II (SII) of the
pseudoknot structure are shown.
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with HindIII and transcribed in the presence of cap analogue as de-
scribed above. The capped T7DC1–341 RNA (16) was prepared simi-
larly. The quality, integrity, and quantity of RNA preparations were
ensured by spectrophotometrically as well as agarose gel electrophore-
sis. The radioactive RNA probes were synthesized under similar reac-
tion conditions with 4-thio-UTP and [a-32P]CTP.
Purification of La Antigen and GST-PTB—A cDNA encoding the
human La antigen without a tag in the pET-8c vector was used for the
expression of recombinant La antigen. The expression of La antigen
was induced by 1 mM isopropyl-1-thio-b-D-galactopyranoside in Esche-
richia coli (BL21(DE3)) cells and purified by a two-step chromatogra-
phy to homogeneity as described previously (42). The expression of
full-length human La (La 1–408) and its truncated versions that con-
tain 6-His tag at the C terminus is described by Goodier et al. (26). The
purification of these proteins were carried out with Ni21-nitrilotriacetic
acid-agarose under nondenaturing conditions and eluted with imidaz-
ole according to manufacturer’s protocol (Qiagen). The La preparations
were dialyzed against buffer D (5 mM HEPES (pH 7.6), 25 mM KCl, 1
mM EDTA, 1 mM dithiothreitol, 10% (v/v) glycerol, 0.2 mM phenylmeth-
ylsulfonyl fluoride, 1 mM leupeptin) and stored in aliquots at 280 °C.
The glutathione S-transferase (GST) and GST-PTB fusion protein were
expressed in bacteria using plasmids GEX-KT and GST-2TK/PTB, re-
spectively, and purified as described previously (43).
UV Cross-linking of Proteins with RNA—4-Thio-UDP (Sigma) was
phosphorylated with nucleoside 59-diphosphate kinase to prepare
4-thio-UTP (44). RNA probes synthesized in the presence of 4-thio-UTP
and [a-32P]CTP were incubated with the purified proteins or lysates at
30 °C for 30 min in RNA binding buffer (buffer D plus 2 mM MgCl2) as
described previously (42). For all the competition assays, competitor
RNAs were added along with the components of the reaction mixture
prior to UV cross-linking. The UV cross-linking was carried out in
Stratalinker (Stratagene) for 30 min at 4 °C. The ribonucleoprotein
complexes were treated with RNase A (10–20 units) (United States
Biochemical Corp.) and analyzed by 12% sodium dodecyl sulfate-poly-
acrylamide gel electrophoresis (SDS-PAGE) followed by autoradiogra-
phy. The intensity of the bands were quantitated by PhosphorImager.
Immunoprecipitation of Cellular La Antigen-HCV 59-NCR Com-
plexes—HeLa S10 cytoplasmic fractions from suspension cultures of
HeLa S3 were prepared essentially as described by Barton et al. (45).
These lysates were active for the HCV IRES-mediated translation of
reporter RNAs. Huh7 cells were cultured on Petri dishes, and the S10
lysates were prepared using the same method. S10 fraction (50 mg of
protein) maintained in RNA binding buffer was mixed with full-length
NCR-C(AUG) RNA probe in a total volume of 50 ml. After UV cross-
linking and ribonuclease treatment, the samples were diluted to 500 ml
with NETS buffer (50 mM Tris-HCl, (pH 7.4), 5 mM EDTA, 1 mM
dithiothreitol, 100 mM NaCl, 0.05% Nonidet P-40), mixed with affinity
purified human anti-La autoantibodies (V3), and incubated at 4 °C for
1 h. The immunocomplexes were immobilized on Protein A-Sepharose
4B beads for 2 h at 4 °C. The unbound materials were washed six times
with the same buffer. The bound protein(s) were analyzed by SDS-
PAGE followed by autoradiography. A parallel reaction mixture was
performed with normal human IgG purified by Protein A-Sepharose
chromatography and served as a control.
Translation—HeLa S10 lysates and initiation factor lysates (45)
were used during translation-inhibition assay. Twenty five ml of the
translation mixture that included 5 ml of the S10 lysates, 3 ml of
initiation factor, 3 ml of 103 CPK (300 mM creatine phosphate, 4 mg/ml
phosphocreatine kinase, 600 mM KCH3CO2, and 155 mM Hepes-KOH,
pH 7.4), 1 ml of [35S]methionine, and 20 units of RNasin, were pro-
grammed with IRES containing luciferase RNA (each 100 ng) in the
absence or presence of varying amounts of C5 SELEX RNA. The reac-
tion was carried out for 1 h at 30 °C , and luciferase activity was assayed
from a 2-ml aliquot as described by de Wet (46). Inhibition of translation
by C5 RNA was plotted against the ligand concentrations. Rabbit re-
ticulocyte lysates (RRL, Promega) were used for translation-stimula-
tion studies in the presence of His-La (1–408) or its truncated versions
as described previously (42). Translation of the capped T7DC1–341 was
carried out using 10 ml of RRL, 2 ml of HeLa S100, 1 ml of [35S]methi-
onine, 1 ml of amino acid mixture without methionine, and 20 units of
RNasin in a total volume of 25 ml for 1 h at 30 °C. Two ml of translation
reactions were subjected to SDS-PAGE (12%) electrophoresis. The gels
were treated with Fluoro-Hance (RPI Corp.), dried, and used for Phos-
phorImage analysis (Bio-Rad).
A liver-derived cell line (Huh7) was used for the co-transfection
assay. The cells were transfected with in vitro transcribed uncapped
T7C1–341 or capped dicistronic dual luciferase RNA using Lipofectin
transfection protocol (Life Technologies, Inc.). To demonstrate the in-
hibitory activity of C5 SELEX or its mutant on the HCV IRES-con-
trolled translation, the cells were directly co-transfected with the re-
porter RNAs along with C5 SELEX. An RNA derived from pGEM-4
multiple cloning site served as a control during a similar co-transfection
experiment. Each transfection was carried out in triplicate. The lucif-
erase activity was assayed as described above.
RESULTS
The C Terminus of La Protein Modulates Its Interaction with
the HCV IRES—La antigen contains three putative RRMs.
RRM1 and RRM2 are located at the N-terminal half of La
protein, and RRM3 is located at the beginning of the C-termi-
nal portion (Fig. 2A). Each of these RRMs plays an important
role during direct recognition of the RNA motifs and increases
the affinity of La during RNA binding by the other RRM (26).
The C terminus contains an adjacent basic and acidic region,
phosphorylation sites, and a homodimerization domain that
regulate its nuclear and cytoplasmic functions (26, 27, 30).
Using various La antigen mutants shown in Fig. 2A, we inves-
tigated if these structural elements play a significant role dur-
ing recognition of the HCV 59-NCR. The bacterially expressed
His-tagged La and those containing deletion mutations were
purified by affinity chromatography using Ni21-nitrilotriacetic
acid resins (26). A silver-stained SDS-PAGE pattern of the
purified proteins is presented in Fig. 2B. The affinity-purified
proteins were UV cross-linked with the wild type 32P-labeled
HCV 59-NCR probe and subjected to SDS-PAGE as shown in
Fig. 2C. La 1–408, which represents full-length wild type La
antigen, binds 59-NCR efficiently. RRM1 represented by La
1–103 alone did not interact with the 59-NCR. However, when
part of the RRM2 was included to the RRM1 in La 1–160,
binding with the 59-NCR probe was observed but with lesser
extent compared with the wild type (La 1–408). Although La
1–235 contains both the RRMs, it exhibited poor binding. Two
additional mutants, La 188–408 and La 229–408, in which
amino acids 187 and 228 were deleted from the N terminus
respectively, efficiently cross-linked with the 59-NCR. These
binding data suggest that affinity of La for the 59-NCR inter-
action is directed more toward the RRM3 than the other two
RRMs that are located at the N-terminal half of La. Contrary to
these observations, the binding of C-terminal half of La protein
to hY4 RNA was not detected in a mobility shift analysis (26).
Using different preparations of La mutants, we further con-
firmed the unusual binding ability of La 188–408 and La
229–408 mutants. Because of the fact that the RNA targets of
La antigen significantly differ from each another in their se-
quence and structural organization, the requirement of cis-
elements within La antigen that regulate its RNA binding
ability may also differ. It is also possible that these diverse
group of RNAs present distinct structural elements for La
binding. This promiscuous binding ability of La may also be an
important element for its distinct nuclear and cytoplasmic
functions. As suggested by competition studies described pre-
viously (Ref. 42, and see below), La antigen appears to make
multiple contacts with the HCV 59-NCR. It is highly likely that
this novel RNA binding domain (RRM3) is able to make direct
contact(s) with the 59-NCR to form ribonucleoprotein complex
that was easily detected by the UV cross-linking assay.
The role of acidic and basic regions of La during 59-NCR
interaction was ascertained by three La mutants containing
substitutions or substitutions plus deletions at the carboxyl-
terminal end. In GXK3DE, glycine and lysine-rich region
(amino acids 328–341) was replaced with alternating aspartate
(D) and glutamate (E) residues while La K3DE contains
amino acids D, E, and D in place of lysine residues at positions
339, 341, and 344, respectively. The mutant, La DDXE3GK
contains deletion of residues 337–367 and residues 368–376
within the acidic region were replaced with alternating gly-
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cines and lysines and juxtaposed to residue 336. The binding of
La K3DE and La DDXE3GK was comparable to the wild type
La antigen, whereas GXK3DE showed considerably reduced
binding to the 59-NCR. These results identify the basic region
as an important element of La protein-HCV 59-NCR
recognition.
Because La 229–408 contains regulatory cis-elements essen-
tial for translational and transcriptional activities of La protein
(26, 27, 30), and because it binds the 59-NCR with affinity
similar to the wild type La (Fig. 2C), we investigated whether
this mutant represents functional elements sufficient for stim-
ulation of the HCV IRES activity. An in vitro synthesized
uncapped monocistronic T7C1–341 RNA, in which the HCV
IRES drives translation of luciferase, was used as a template
during translation stimulation studies in RRL. The RRL con-
tains suboptimal levels of La protein and has been previously
used as a suitable system for similar studies (27, 40, 42). The
translation of the HCV IRES-driven luciferase RNA was in-
creased modestly, by 2.5-fold in the presence of La 229–408
(Fig. 3, lanes 3–5) compared with the basal translation without
the exogenously added La (lane 2). However, the full-length La
stimulated .6-fold at similar concentration of the protein
(lanes 6–8). The La-stimulated HCV IRES activity was com-
pletely blocked by monoclonal La antibody (SW5) but not by a
nonspecific control (data not shown). These data support the
stimulatory role of La binding during the HCV IRES-driven
translation initiation (42). Further, these data also demon-
strate that the N-terminal half of La antigen is important for
translational stimulatory activity of La. While the C-terminal
half binds the 59-NCR efficiently, it is unable to stimulate
translation at wild type levels.
The La Antigen Targets Initiator AUG but Not the Flanking
Nucleotides for Its Binding to the HCV RNA—We have previ-
ously shown La antigen interaction with the HCV 59-NCR in
the context of the initiator AUG (42). To further characterize
this unique pattern of interaction, several additional 59-NCR
mutants were used during competition assay. A mutant RNA
representing a full-length wild type HCV 59-NCR that lacked
the initiator AUG codon (NCR-C(DAUG)) was used as a com-
petitor for La binding to the thio-U-containing 32P-labeled HCV
FIG. 2. Interaction of La antigen mutants with the wild type
HCV 5*-NCR. A, His-La mutants used during direct UV cross-linking
of the HCV 59-NCR probe. The three putative RRMs and the adjacent
acidic (111) and the basic (2 2 2) regions at the C-terminal end are
elaborated. B, SDS-PAGE pattern of the purified His-La proteins. The
purified proteins (100 ng) were subjected to electrophoresis and stained
with silver staining method to visualize the protein bands. C, direct UV
cross-linking of the purified His-La proteins and its truncated mutants
with the NCR-C(AUG) RNA probe. One hundred nanograms each of
full-length His-La (La 1–408) and the truncated versions were UV
cross-linked with the RNA probe and fractionated by SDS-PAGE after
digestion with RNase. The dried gel was exposed for autoradiography.
FIG. 3. Translational trans-activation of the HCV IRES-con-
trolled luciferase RNA in RRL by full-length and C-terminal half
of La antigen. Translation of the HCV IRES-luciferase RNA (T7C1–
341) with increasing amounts of bacterially expressed purified full-
length His-La antigen (lanes 6–8) or its truncated version representing
C-terminal half (lanes 3–5). Lane 1, no template RNA; lane 2, without
added His-La antigen. The translation was carried out with 50 ng in
vitro transcribed uncapped T7C1–341 RNA in RRL and the translation
products were radiolabeled with [35S]methionine. The final volume (20
ml) of the reaction mixtures was adjusted with RNA binding buffer (see
“Materials and Methods”). Ten microliters of translation mixtures were
fractionated by 12% SDS-PAGE. The gels were treated with Fluoro-
Hance (RPI Corp.) before autoradiography. Luciferase activity was
measured with a 2-ml aliquot of the translation mixture according to de
Wet et al. (46).
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IRES (NCR-C(AUG)) probe (Fig. 4A). The intensities of binding
signal due to cross-linking of La with the wild type probe
progressively decreased at increasing concentrations of the un-
labeled homologous competitor RNA (Fig. 4A, lanes 2–4). How-
ever, AUG deletion containing mutant RNA showed consider-
ably low level of competition (lanes 5–7). Consistent with our
previous findings, the results with these additional mutants
show that initiator AUG at this position is required for La
interaction. Interestingly, a series of mutant RNAs, which re-
tained the initiator AUG but had 3-nt deletion in its vicinity,
showed La binding similar to the wild type 59-NCR (Fig. 4B).
Additional mapping analysis further suggested that nt 1–120
from the 59 end of the NCR do not contribute to the La binding.
The disruption of the helical structure within the stem 1 of the
pseudoknot marginally affected La-59-NCR interaction. Simi-
larly, several substitutions from pyrimidines to purines within
the apical loop of domain III also showed no effect on La
binding (data not shown). These results clearly suggest that
the La binding is focused on initiator AUG and the structural
elements located within the domains III and IV.
Multiple Forms of Cellular La antigen Bind the HCV 59-
NCR—Since the functional significance of La antigen interac-
tion to the 59-NCR was investigated in both the liver-derived
(Huh7) and non-liver-derived (HeLa) translation systems (see
below), we first determined the presence of La protein in the
cytoplasmic fractions (S10) of these cell lines. The S10 lysates
were UV cross-linked with thio-U-containing 32P-labeled wild
type HCV 59-NCR (NCR-C(AUG)) and immunoprecipitated us-
ing affinity-purified human La antibodies (V3) (Fig. 5). Two
closely migrating UV cross-linked 59-NCR-La complexes of the
HeLa S10 at 50/52 kDa were observed following immunopre-
cipitation with the human La antibodies (lane 4) but not with
the normal human IgG (lane 3). When Huh7 S10 lysates were
used during this assay, a 43-kDa and a 50-kDa UV cross-linked
proteins were immunoprecipitated (lane 2). These results are
consistent with our previous observations of a predominant
43-kDa La protein from Huh7 cell line bound the HCV 59-NCR.
Interestingly, this La-59-NCR complex was not immunoprecipi-
tated from the HeLa S10 preparation after UV cross-linking
with the 59-NCR. However, one of the two 50/52-kDa HeLa
S10-derived La antigens that were bound to the probe was also
detected in Huh7 S10 (compare lanes 2 and 4). Using immuno-
blot assay in earlier studies, Pruijn (55) also demonstrated the
existence of only 52-kDa La species in HeLa cell lysate whereas
several other cell lines were shown to contain both 50/52-kDa
as well as 43-kDa La in their lysates. Thus, the 52-kDa La form
that was used for binding assay appears to be expressed in both
the cell lines. The diversity and the origin of these La forms are
not clearly understood. However, results from several labora-
tories suggest that different La proteins may result from alter-
native splicing, phosphorylation, or cleavage at the PEST sites
within the C terminus (30, 47, 55).
La Antigen Is Required for the HCV IRES-mediated Trans-
lation—As shown above, La antigen directly interacts with the
critical components of the HCV IRES and stimulates its activ-
FIG. 4. La antigen binds the HCV 5*-NCR in the context of the
initiator AUG. A, competition assay using mutant RNA lacking initi-
ator AUG. Purified human recombinant La preparation expressed in
bacteria was UV cross-linked with the wild type 59-NCR RNA probe and
fractionated by 12% SDS-PAGE after digestion with RNase. The NCR-
C(AUG) probe contained 4-thio-U and was labeled with [32P]CTP. The
binding reactions were carried out with 15 ng of purified La. Lane 1, no
competitor RNA; lanes 2–4, homologous competitor; lanes 5 and 6,
mutant 59-NCR. Upper panel shows the nucleotide sequence at the 39
end of the wild type NCR-C(AUG) and the AUG deletion (indicated with
dash) containing mutant RNA (NCR-C(DAUG)). The band intensities
were calculated using PhosphorImager. The numbers in the upper
panel indicate nt position in the HCV RNA. B, effect of deletion of nt
sequences surrounding initiator AUG on La protein binding with the
wild type probe. The 3-nt deletions in each of the mutant 59-NCR are
shown by dashed line in upper panel. These RNAs were used as unla-
beled competitors during the competition assay as described above.
Lane 1, no competitor RNA; lanes 2–4, increasing amounts of unlabeled
homologous RNA; lanes 5–16, mutant RNAs as competitors.
FIG. 5. Immunoprecipitation of La antigen from a liver cell-
derived (Huh7) and a non-liver derived (HeLa) S10 fractions
after UV cross-linking with the 4-thio-U-containing 32P-labeled
HCV 5*-NCR probe. UV cross-linked Huh7 (lanes 1 and 2) and HeLa
(lanes 3 and 4) lysates were subjected to immunoprecipitation with
human anti-La antibodies (V3) (lanes 2 and 4) or normal human IgG
(lanes 1 and 3). The samples were fractionated by SDS-PAGE and
autoradiographed. Normal human IgG (NHIgG) was isolated from a
serum of healthy individual by Protein A-Sepharose chromatography.
Anti-La antibodies were isolated from autoimmune sera by affinity
chromatography using recombinant human La as a ligand.
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ity to a considerable extent. Thus, it is conceivable that La
protein might be required for the HCV IRES activity. To ini-
tiate these studies, we first used full-length 59-NCR as a com-
petitor during translation of T7C1–341 (Fig. 6) in RRL. The
basal level of the HCV IRES activity (lane 2) as determined by
the translation of luciferase was completely inhibited by the
59-NCR competitor (lane 3). This inhibition was rescued by the
addition of recombinant human La antigen (lane 4), but not by
an unrelated protein or bovine serum albumin (data not
shown). This La add-back experiment clearly indicates that La
antigen has functional requirement for the HCV IRES
function.
To further characterize La antigen requirement for the HCV
IRES function, we explored the possibility whether SELEX
RNA molecules could serve as a specific reagent that can se-
quester La protein in the translation lysates, thereby rendering
its function during the HCV IRES-controlled translation initi-
ation process. SELEX is an in vitro selection procedure that
leads to isolation of oligonucleotides with selective affinity for a
given target. In this study, we have used a C5 SELEX RNA
generated against La antigen that binds the protein with high
affinity.2 The C5 SELEX contains dual recognition motifs for
La antigen; motif I contains CACAA target, whereas motif II is
located at the 39 end of the RNA ending with terminal
UAAUUU residues. The overall structure of C5 SELEX resem-
bles with a typical tRNA. The SELEX binds only La protein in
the HeLa translation lysates. This conclusion was derived from
direct UV cross-linking of C5 SELEX probe with HeLa S10
fraction and subsequent immunoprecipitation by La antibodies
(Fig. 7A). The binding specificity of the C5 RNA was further
determined in a competition assay. La antigen binding to the
wild type HCV 59-NCR probe was successfully inhibited by the
C5 RNA (Fig. 7B, compare lanes 2–4 with the homologous
competitor shown in lanes 5–7). Since PTB was previously
shown to bind the 59-NCR at multiple sites (43), we used a
similar competition assay as a control. The PTB interaction to
the probe was not affected by C5 RNA even at 200 M excess
(Fig. 7C, lanes 2–4). However, under similar conditions, the
homologous competitor showed higher degree of competitive
inhibition (lanes 5–7). These results clearly demonstrate the
specificity of C5 RNA to bind La antigen with high affinity and
further indicate that the C5 ligand may not perturb the struc-
tural integrity of the 59-NCR, as it permits PTB interaction.
Because of these specific features, we used C5 RNA as a specific
probe to determine the requirement of La during HCV IRES-
controlled translation.
The C5 SELEX RNA was introduced into HeLa S10 lysates
during translation of the HCV (T7C1–341), poliovirus
(T7P5NCLuc), and TMEV (PB305) IRES-controlled luciferase
reporter RNA. In this experiment, poliovirus IRES-Luc was
used as a positive control because of its well characterized
interaction with La antigen. The translation of TMEV IRES-
controlled luciferase occurred efficiently in the presence of C5
SELEX RNA (Fig. 7D). However, the translation of HCV and
poliovirus IRES-containing luciferase RNA was diminished
with increasing concentrations of the C5 SELEX ligand under
similar translation conditions. Thus, addition of C5 RNA to the
lysates specifically sequestered La antigen that was required
for the poliovirus and the HCV IRES function. Interestingly,
general translational machinery was not affected by the
SELEX RNA, as evidenced by the continued translation of the
TMEV IRES-controlled reporter cistron. A similar inhibitory
pattern of the HCV IRES by C5 RNA was also detected in RRL
(data not shown).
The ability of C5 SELEX to inhibit the HCV IRES activity
was also tested in the context of a capped dicistronic mRNA
(T7DC1–341). The upstream cistron (CAT) of this mRNA is
translated by cap-dependent mechanism, whereas the transla-
tion of downstream luciferase (LUC) coding region is dictated
by the HCV IRES (16). The translation of luciferase of the
capped T7DC1–341 mRNA was found to be efficient in the
HeLa translation system that was completely abolished by the
C5 SELEX. However, cap-dependent translation of CAT was
inefficient under these conditions. This phenomenon was also
observed when capped Brome mosaic virus mRNAs were used
as templates for translation in HeLa lysates (data not shown).
We, therefore, utilized reticulocyte translation system supple-
mented with the HeLa S100 as a source of cellular factors
including La antigen. The translation of T7DC1–341 was then
investigated in the presence of either wild type C5 SELEX or a
mutant C5 RNA (Fig. 7E). The C5 mutant lacks La recognition
motif II, which is located at the 39 end of the RNA. Since motif
I (the internal site for La recognition) remains intact in this
mutant, its overall structure and stability remain similar to
that of wild type SELEX molecule except that this mutagenesis
resulted in a moderate lose of affinity for La antigen. The wild
type C5 SELEX dramatically inhibited translation of the lucif-
erase but not the CAT cistron (lanes 3 and 4). The C5 mutant,
however, was less effective in inhibiting the HCV IRES-de-
pendent translation compared with that of wild type C5 (com-
pare lanes 5 and 6 with lanes 3 and 4). The mutant SELEX also
failed to inhibit cap-dependent translation of CAT cistron
(lanes 5 and 6). These observations further reiterate the spe-
cific inhibition of the HCV IRES function by C5 SELEX by
sequestering La antigen without inhibiting general translation
process.
Since HCV targets human hepatocytes for completing its
life-cycle, we further investigated if La antigen is required for
the HCV IRES activity in vivo. To address this question, a
human liver-derived cell line (Huh7) was co-transfected with
T7C1–341 (HCV IRES-luciferase) and C5 SELEX or a control
RNA of similar length derived from pGEM-4 vector. The cell
lysates were assayed for the HCV IRES-dependent luciferase
expression. The HCV IRES activity was specifically inhibited
by the C5 RNA but not by the control RNA (unrelated) (Fig.
8A). The TMEV IRES, which served as a negative control in our
in vitro assay (Fig. 7D), was found to be inactive in Huh7 cells
after repeated transfection studies. However, other controls
such as poliovirus IRES were efficiently inhibited by the C5
SELEX (data not shown). A dual luciferase assay system was
employed to further evaluate the specificity of C5 SELEX in-
hibitory activity. In vitro transcribed capped RL-1b contains
upstream Renilla luciferase that is translated by cap-depend-
FIG. 6. Rescue of the HCV IRES activity by recombinant hu-
man La antigen. The T7C1–341 RNA was translated in RRL as
described in the legend to Fig. 3. The template RNA was translated in
the absence (lane 2) or presence (lane 3) of full-length wild type 59-NCR
(competitor). Lane 4 is similar to lane 3 except that recombinant human
La antigen (100 ng) was added to counteract the inhibition by the
competitor 59-NCR. A similar concentration of bovine serum albumin
failed to counteract such inhibition (data not shown). Lane 1, transla-
tion without T7C1–341 RNA template as a control.
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ent mechanism, whereas the translation of downstream firefly
luciferase is controlled by the HCV IRES (Fig. 8B, upper panel).
During transfection studies as described above, a dramatic
inhibition of the HCV IRES in the context of the dual reporter
RNA was observed by wild type (WT) C5 RNA (Fig. 8B),
whereas the mutant (Mut) C5 exhibited moderate inhibitory
activity similar to that seen during our in vitro analysis (Fig.
7E). Interestingly, the moderate inhibition of cap-dependent
translation was also observed by both WT as well as Mut C5
SELEX. A possible explanation of such inhibition could be that
La antigen targets initiator AUG codon embedded in the con-
text of Kozak consensus sequence (ACCAUGG). The recogni-
tion of AUG by La antigen is thought to be involved for the
start-site selection during cap-dependent translation (48).
Therefore, it could be possible that C5 SELEX may have inter-
fered with La antigen binding to the initiator AUG during
cap-dependent translation. These results, which are consistent
with the in vitro inhibition data presented in Fig. 7D, provide
an in vivo evidence that La protein is an essential feature of the
HCV IRES-mediated translation. Taken together, La antigen
requirement for the HCV IRES was established in the context
of several reporter constructs both in vitro as well as in living
cells.
DISCUSSION
In this study, we have demonstrated novel features of the
La-HCV IRES interaction and their functional consequences
during the IRES-controlled translation. Although several cel-
FIG. 7. Inhibition of the HCV IRES activity by sequestration of La antigen with the C5 RNA SELEX. A, C5 RNA SELEX binds only
La antigen in the HeLa lysates. HeLa S10 lysates were UV cross-linked with thio-U and 32P-labeled C5 RNA (lane 1). A similar cross-linked sample
was immunoprecipitated using normal human IgG (lane 2) or human anti-La antibodies (lane 3). Lane M, molecular weight markers. B,
competitive inhibition of La-59-NCR interaction by C5 RNA (lanes 2–4) during UV cross-linking of the wild 59-NCR probe with La antigen. Lanes
5–7 shows competition with the homologous RNA. C, specificity of the C5 RNA binding. GST-PTB interaction with the 59-NCR (lane 1) is inhibited
by the homologous competitor (lanes 5–7) but not with the C5 RNA (lanes 2–4). GST alone does not interact with the HCV 59-NCR (43). D, selective
inhibition of the La antigen-dependent IRES activity. In vitro transcribed uncapped viral IRES-containing luciferase RNAs (100 ng each) were
translated in HeLa cell lysates in the presence of 1, 2, and 3 mg of C5 RNA. The luciferase activity in the C5 RNA containing samples was compared
with sample without the ligand that was set at 100% activity. The template RNAs used in this experiment are indicated with the plot. The results
presented here are representative of several repeats. E, inhibition of the HCV IRES by C5 SELEX RNA in the context of dicistronic mRNA
template. In vitro transcribed capped T7DC1–341 RNA (1 mg) was translated in rabbit reticulocyte lysates supplemented with HeLa S100 (lane
2). The HCV IRES activity is represented by the translation of luciferase (LUC), while chloramphenicol acetyltransferase (CAT) is translated by
cap-dependent mechanism. Lane 1, translation without RNA. The RNA template was translated in the presence of 2 mg (lane 3) and 4 mg (lane 4)
of WT C5 SELEX RNA or similar concentrations of the mutant C5 RNA (lanes 5 and 6), respectively. The translation of luciferase and
chloramphenicol acetyltransferase were quantitated by autoradiography of the gel directly exposed to the PhosphorImager screen (Bio-Rad). The
translation of the control without inhibitors (lane 2) was considered as 100% and compared with lanes 3–6.
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lular factors have been recently shown to interact with the
HCV 59-NCR, the binding of La antigen appears to have fun-
damental impact on the IRES efficiency. These conclusions are
based on the extensive mutational analysis and the strong
inhibitory effect of SELEX RNA that sequesters La antigen
with high affinity.
La antigen has been shown to be evolutionarily conserved
from yeast to human, and its presence in the nucleus as well as
cytoplasm of a wide variety of cell types has been documented
(55). Because Huh7 and HeLa cells support HCV IRES-medi-
ated translation (Ref. 12 and Fig. 7D), we investigated the
possible existence of various forms of La that may bind the
HCV 59-NCR in a translationally active cellular extracts. At
least three forms of La antigen were found to interact with the
HCV 59-NCR: two forms migrating at 50/52 kDa from HeLa
lysates, and a 43-kDa form that was found only in Huh7 ly-
sates. One of the 50/52-kDa form found in HeLa extract was
also observed in the Huh7 lysates. Fan et al. (30) have previ-
ously demonstrated that HeLa cells contain phosphorylated
and unphosphorylated forms of La antigen. Although both the
states of La antigen differ in their transcriptional activity,
these La forms were equally active for RNA binding. However,
both the La forms were shown to have similar electrophoretic
mobility on SDS-PAGE. Thus, it appears that the two 59-NCR-
bound La species from HeLa S10 lysates (Fig. 5) could be
alternately spliced RNA encoded isoforms. The 43-kDa La is
thought to be the cleavage product of the 50/52-kDa form. The
functional importance of three La species described above in
the context of their binding to the 59-NCR remains to be inves-
tigated in detail.
Several lines of evidence presented here demonstrate that
initiator AUG codon is an essential component of La antigen’s
recognition motif within the HCV 59-NCR. Since complete in-
hibition of La interaction was not achieved when initiator AUG
was deleted (Fig. 4A) or substituted to AAG/AUU (42), it is
likely that additional cis-elements of the 59-NCR may be re-
quired for La binding to the 59-NCR. Several mutants contain-
ing deletions from 59 end, and substitutions in the pseudoknot
structure of the 59-NCR were used to address this problem. The
deletion of either oligopyrimidine-II tract (Py-II, Fig. 1) or
substitutions that disrupt the base pairing in the stem I of the
pseudoknot (17) only affected the La binding modestly. Using
synthetic RNA molecules as a substrate, McBratney and Sar-
now (48) noted that La antigen interacts with the AUG triplet
and that this interaction was influenced by the Kozak sequence
context. In this study, the deletion of triplets surrounding AUG
codon failed to affect La interaction. The three 59-NCR mu-
tants, NCR-C(DC2), NCR-C(DC3), and NCR-C(DC4), that
showed efficient binding with La antigen had complete AC-
CAUGA Kozak sequence except that they lacked in specific
codon (see Fig. 4B, upper panel). Interestingly, the deletion
mutant NCR-C(DACC), despite having UGCAUGA in place of
usual ACCAUGA, interacts efficiently with La antigen.
Svitkin et al. (40) have shown that N-terminal half of La
antigen (amino acids 1–194) binds poliovirus 59-NCR but fails
to correct or stimulate the translation initiation. In this study,
we demonstrate that the mutant protein representing C-termi-
nal half of La antigen (La 229–408) also binds the 59-NCR
efficiently and modestly stimulates the HCV IRES-directed
translation in RRL. The C-terminal half of La protein functions
as an effector part of La antigen during poliovirus IRES-medi-
ated translation and contains a dimerization domain that
spans between amino acids 226 and 348 (27). In light of these
observations, one can argue that if La binding to the IRES
elements and its homodimerization via C-terminal domain are
the only criteria for its translational stimulation activity, La
229–408 should achieve a translation stimulation similar to
the wild type. However, we observed that stimulatory activity
of the La 229–408 was comparatively lower. Thus, C-terminal
effector domain is important, as suggested by previous studies
(27, 40), but in addition to this domain, N-terminal half of La
antigen may also play an important role during IRES-mediated
translation. This is also supported by the interaction between
La 1–160 mutant and the 59-NCR (Fig. 2C).
The functional importance of La binding to the HCV 59-NCR
was demonstrated by the translation-stimulation studies in
which severalfold increase in the HCV IRES activity was ob-
served in the presence of recombinant human La protein in
RRL (Fig. 3). Because of the fact that RRL contain compara-
tively little La protein than HeLa lysates, the effect of recom-
binant La was more pronounced in this system. Belsham et al.
(49) attempted La depletion strategy to demonstrate the func-
tional importance of La protein during poliovirus IRES-medi-
FIG. 8. In vivo inhibition of the HCV IRES by C5 SELEX. A, the
Huh7 cells cultured on 60-mm Petri dishes were transfected with
T7C1–341 (3 mg) alone (control) or co-transfected with C5 SELEX or
pGEM-4 RNAs (15 mg each). Luciferase activity in the cytoplasmic
lysates was assayed to determine the HCV IRES efficiency after 16 h of
transfection. The “unrelated” control represents 75 nt of RNA derived
from the multiple cloning site of pGEM-4 vector. Each transfection
experiment was carried out in triplicate and standard error was calcu-
lated. The standard error for C5 SELEX is calculated to be ,1% and is
not visible on this scale. B, 3 mg of capped dual luciferase reporter RNA
(upper panel) was transfected into Huh7 cells either alone (control) or
co-transfected with WT or Mut C5 SELEX RNA (4 mg) as described
above. Each transfection was carried out in duplicate. The enzymatic
activities of Renilla (RL) and firefly (FL) luciferase were assayed from
an equal amount of protein sample using dual-luciferase reporter assay
system (Promega). The transfection experiments were repeated several
times.
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ated translation. In that assay, La antigen was immunode-
pleted from HeLa lysate. Interestingly, the La depletion
dramatically abolished the translation ability of the lysate,
which was not rescued by the addition of purified La protein.
The explanation was that such an approach suffers from the
removal of La-associated factors that may be essential ele-
ment(s) of translation initiation. A La depletion/add-back ap-
proach was also employed by Das et al. (50) during their studies
on the inhibition of the HCV IRES-mediated translation by
yeast I-RNA, which strongly binds human La antigen. In this
experiment the translation lysates were passed through an
I-RNA affinity column, and the flow-through that was assayed
for HCV IRES function failed to support translation. During an
add-back experiment described here (Fig. 6), again the HCV
IRES activity was rescued to the basal level that suggested the
requirement of additional factor(s) for the stimulated transla-
tion. In light of the failure of some of these approaches, we
sought an alternative strategy of employing SELEX RNA mol-
ecules with high affinity to La protein to establish the require-
ment of La antigen for the HCV IRES activity in vivo. We have
utilized a high affinity RNA ligand, termed C5 SELEX RNA,
that binds to the La antigen (Fig. 7A). This approach allowed us
to provide two additional lines of evidence in support of the
functional role of La protein in the HCV IRES-mediated trans-
lation. First, the sequestration of La in the HeLa translation
mixture was achieved by the addition of large amounts of
SELEX RNA. This led to a dramatic decrease in the HCV and
poliovirus IRES functions, whereas cardiovirus (TMEV) IRES
activity was unaffected. We further demonstrate an in vivo
inhibition of the HCV IRES activity by the C5 SELEX but not
by an unrelated control RNA. These studies together provide
unequivocal evidence for the requirement of La in vivo for
efficient HCV IRES function.
The HCV 59-NCR has been shown to form ribonucleoprotein
complexes with several cellular factors including La antigen
and PTB (42, 43). Recently, in vitro reconstitution studies by
Pestova et al. (51) revealed a direct interaction of 40 S riboso-
mal subunit via S9 protein that is located on the other end of
the mRNA binding cleft from the eIF-3 binding site. In a
similar study, four subunits of the eIF-3 (p170, p116, p66, and
p47) were also shown to make direct contact with the apical
half of the domain III of the 59-NCR (52). In our studies, we
observed that La antigen binding to the 59-NCR was unper-
turbed when increasing concentrations of 40 S ribosomal sub-
unit were added to the assay mixture (data not shown). These
and other studies suggest that the interactions of cellular pro-
teins may be directed toward specific sites in the 59-NCR.
Furthermore, eIF-3 and La antigen are known to associate
with native 40 S ribosomal subunit in the cytoplasm (1, 31).
Since structural integrity of the 59-NCR is important for its
IRES function, it is highly likely that the structural elements of
the HCV IRES provide a “docking facility” for the ribosomes.
The ribosomal docking must be mediated by these cellular
factors to direct the complex to the designated initiation site. In
this scenario, La antigen may be functioning as a molecular
chaperon during assembly of the ribosomal complex directly at
the initiation site.
Based on the inherent feature of La antigen for its ability to
unwind the double stranded RNA in a ATP-dependent manner
(24), it is conceivable that the La binding to the translation
initiation site provides additional advantage for the initiation
complex in acquiring RNA helicase activity. Interestingly, the
flanking sequences of the initiator AUG form a stable stem-loop
structure (Ref. 53; Fig. 1, Domain IV) and this structure must
be melted away to facilitate translocation of the 80 S complex to
the second and subsequent codons. Indeed, Honda et al. (53)
demonstrated that the mutations that destabilize this stem-
loop structure promote the IRES efficiency. Thus, because of
strategic binding and its double-stranded RNA helicase activ-
ity, La antigen may play a pivotal role in accelerating transla-
tion efficiency of the HCV IRES. A more plausible role of La
protein may be that it functions like an RNA chaperon in
positioning the translation machinery at the start site. This
study further revealed a unique property of La antigen during
RNA recognition through its putative RRM3 motif. Extensive
mutagenesis of RRMs and the C-terminal regulatory elements
is needed to further delineate the functional importance of
these motifs during HCV IRES-driven translation. That re-
mains the goal of our future investigation.
In summary, the present study and a previous report (42)
provide several lines of evidence, which suggest that initiator
AUG is the primary target of the La protein, and that addi-
tional structural motifs of the IRES such as domains III and IV
must play significant role(s) during this recognition. The C
terminus effector domain plays a pivotal role during La-59-NCR
interaction. The requirement of La for the HCV IRES was
established using the C5 SELEX RNA, which sequesters La
protein both in vitro and in vivo. The La antigen add-back
experiment reiterated these observations.
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